A dynamic Markov model for forecasting diabetes prevalence in the United States through 2050.
about
Nonalcoholic Fatty liver disease and risk of diabetes and cardiovascular disease: what is important for primary care physicians?Monitoring progress toward CDC's health protection goals: health outcome measures by life stagePopulation attributable fraction of type 2 diabetes due to physical inactivity in adults: a systematic reviewA new approach of nonparametric estimation of incidence and lifetime risk based on birth rates and incident events.Modeling transition rates using panel current-status data: how serious is the bias?Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence.Mortality and morbidity trends: is there compression of morbidity?American ginseng stimulates insulin production and prevents apoptosis through regulation of uncoupling protein-2 in cultured beta cells.Identification of barriers to appropriate dietary behavior in low-income patients with type 2 diabetes mellitusAntihyperglycemic effects of Pandanus amaryllifolius Roxb. leaf extract.Projection of Diabetes Population Size and Associated Economic Burden through 2030 in Iran: Evidence from Micro-Simulation Markov Model and Bayesian Meta-AnalysisImpact of the population at risk of diabetes on projections of diabetes burden in the United States: an epidemic on the way.Computer-administered screening of reproductive-aged women for diabetes risk in primary care settings, feasibility and acceptability of such screening, and validity of risk assessments based on self-reported weight.Charting plausible futures for diabetes prevalence in the United States: a role for system dynamics simulation modelingImproving Detection of Prediabetes in Children and Adults: Using Combinations of Blood Glucose Tests.Burden of type 2 diabetes in Mexico: past, current and future prevalence and incidence ratesAssociation between renal failure and foot ulcer or lower-extremity amputation in patients with diabetes.Emerging drugs for the treatment of diabetic ulcers.Maintaining a physiological blood glucose level with 'glucolevel', a combination of four anti-diabetes plants used in the traditional arab herbal medicine.Epidemiology of diabetes and diabetes-related complications.Ginseng on hyperglycemia: effects and mechanismsThe prevention of type 2 diabetes: an overview.Racial comparisons of diabetes care and intermediate outcomes in a patient-centered medical home.Protective role of physical activity on type 2 diabetes: Analysis of effect modification by race-ethnicity.Prevalence of type 2 diabetes in Germany in 2040: estimates from an epidemiological model.Projection of prediabetes and diabetes population size in Singapore using a dynamic Markov model.American ginseng modulates pancreatic beta cell activities.Projection of osteoporosis-related fractures and costs in China: 2010-2050.Quality of care of Medicare patients with diabetes in a metropolitan fee-for-service primary care integrated delivery system.Projection of the future diabetes burden in the United States through 2060.Matrix models and sensitivity analysis of populations classified by age and stage: a vec-permutation matrix approachAmerican Diabetes Association–Cure–Care–Commitment
P2860
Q26827169-D8AA446F-46BD-4F61-B52F-0FC5C26666ECQ30228128-95B15134-202E-42F2-8DB2-45AB0F56C6C3Q30363110-01EC5AE0-8BB2-4FDA-9738-1059E578A2D7Q33311594-3D47D3B6-2A71-4662-AB3D-BF994E9E53DCQ33699890-6FBF0C10-EAD0-413A-A724-3BEB20671B8FQ34321390-07571264-02FD-492C-993F-BA551BF4DAD7Q34405248-305AD9AB-7BD0-4CAD-851C-97EF0A4C675EQ34803578-6AFAA413-B551-44BD-8609-18D0BF126844Q35072293-A43DAB28-B8BF-4A92-A8F5-672BA33DBAE6Q35086806-52664AFA-268C-4EAF-992A-055949876222Q35705650-5A8AD03E-7D21-44B9-979C-59285B8CAC56Q35744421-9C5B0BB4-BFEB-436F-BFB5-59E02B2C62B5Q35955630-6A9C6483-905F-4534-B6BC-E77E6F188738Q35955743-3AC54962-8A5A-4166-872F-E6840FF1175EQ36302134-08B498CD-2518-4E83-9F03-148556025B31Q36373206-F10A1A05-ADC2-46F6-B382-AE974A140131Q36756681-53F34F02-EA62-468D-BDED-41BDA3B2259EQ36968989-4B52BCB3-1290-4D54-A478-228C7C387383Q36981112-ADE09ABF-9BA0-44D7-ADCC-3819C99009C6Q37273009-504A47E9-7A52-4EC9-A466-5D90BCA3103DQ37309905-EE48CBE9-AD86-4FEA-844E-7110D66B9A1FQ37404550-58D1FA82-4862-4325-866F-2BF1D1232A27Q37660883-292B5A21-D99F-4109-ADB6-A6274B316218Q39330066-DFB8EBFF-4219-48C5-83E4-1BCF4CF3C4E6Q39571759-1161DB7D-42ED-4ABE-A233-D4394216FB1BQ40020513-A967AF4C-E981-4F69-BEEF-D003BECE94F7Q40660633-0875D068-5FCD-4442-925F-B458FA80072BQ41243465-67CBE356-DEC1-403E-8507-432044D4DAE2Q46798741-C68C011E-7A97-4580-BC3C-2C7542A26185Q55467652-D3C4AD4B-CB49-4820-974A-103E7BC3CAF8Q58055195-32FBD31E-B931-4664-B863-5F008A0DE3E2Q58563902-53F833D0-9DC3-44DE-BF04-799F359DCEA1
P2860
A dynamic Markov model for forecasting diabetes prevalence in the United States through 2050.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
A dynamic Markov model for for ...... he United States through 2050.
@en
type
label
A dynamic Markov model for for ...... he United States through 2050.
@en
prefLabel
A dynamic Markov model for for ...... he United States through 2050.
@en
P2093
P356
P1476
A dynamic Markov model for for ...... he United States through 2050.
@en
P2093
Amanda A Honeycutt
James P Boyle
K M Venkat Narayan
Kristine R Broglio
Theodore J Thompson
Thomas J Hoerger
P304
P356
10.1023/A:1024467522972
P577
2003-08-01T00:00:00Z